NUVB - Rasio rega marang prakiraan pendapatan Nuvation Bio

Nuvation Corp (NUVB) - logo korporat

Can the academic culture of Nuvation Bio Inc. (NUVB) and its bet on talent drive growth? This forward price-to-sales chart provides the answer, with the metric currently standing at 7.00. High costs and patent risks create steep barriers to entry. Meanwhile, Nuvation Bio Inc. (NUVB) is implementing robotic molecule screening to combat resistant tumors, optimizing its laboratory processes.

Nuvation Bio Inc - Prakiraan rega marang pendapatan NUVB (periode 06.08.2024 - 14.11.2026)

Rincian metrik komprehensif lan analitis Nuvation Corp (NUVB)

- rega pasar lan target rega analis:
Bagan rega Nuvation Bio|NUVB - Bagan rega target
- statistik kapitalisasi pasar:
Nilai pasar Nuvation Corp|NUVB - Total Nilai Perusahaan
- indikator nilai buku ekuitas:
Nilai Buku saben Saham Nuvation Bio|NUVB - Nilai Buku Bisnis|Rasio Kapitalisasi marang Aset Bersih nuvationbio.com|NUVB - Aset Perusahaan
- data utang lan likuiditas:
Rasio Total Utang marang Ekuitas Nuvation Bio Inc.|NUVB - Koefisien utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Nuvation Bio Inc.|NUVB - Tanggungan utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Nuvation Corp|NUVB - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Nuvation Bio|Likuiditas cepet nuvationbio.com
- rincian asil keuangan lan kelipatan valuasi:
NUVB - Bathi pungkasan|Proyeksi bathi mangsa ngarep Nuvation Bio Inc.|NUVB - Pangali P/E|Rega marang bathi mangsa ngarep Nuvation Pharma|NUVB - Rasio kapitalisasi marang bathi lan wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Nuvation Corp|NUVB - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Nuvation Bio|NUVB - Bathi saben saham sajrone 12 wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan nuvationbio.com|NUVB - Wutah bathi ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Nuvation Bio Inc.
- data pendapatan lan penerimaan dodolan:
NUVB - Pendapatan perusahaan|Prakiraan volume dodolan Nuvation Bio|NUVB - Multiplikator P/S|Multiplikator forward rega marang pendapatan Nuvation Corp
Analisis umum perusahaan:Nuvation Bio NUVB
Produk sing diprodhuksi nuvationbio.com

To protect capital amid uncertainty, it is critical to distinguish between undervaluation and systemic business decline. The forward P/S ratio compares market value with expected revenue, revealing the extent of an asset's overvaluation. Analyzing the projected price-to-sales ratio helps determine whether a price drop is a "value trap." For Nuvation Bio Inc. (NUVB), which has no commercial products, this indicator reflects the speculative value of future developments supported by current investment capital.

Pesaing wigati

Rasio rega marang prakiraan pendapatan Incyte INCY|Hutchison MediPharma - Rasio rega marang prakiraan pendapatan|DAWN - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Monopar Corp|INBX: Multiplikator Forward P/S|Prakiraan rega marang pendapatan I-Mab Biopharma IMAB|Multiplikator forward rega marang pendapatan FENC|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Heron Therapeutics Inc HRTX|Multiplikator forward rega marang pendapatan NVCT (Nuvectis)|CHRS (Coherus BioSciences, Inc) - Rega forward marang dodolan|Corbus Pharmaceuticals - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake CRDF (Cardiff Oncology Inc.)|BeyondSpring - Multiplikator Forward P/S|Rega forward marang dodolan BCAB (BioAtla, Inc.)|LIXT: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Citius Pharmaceuticals, Inc. (CTXR)|Rasio rega marang prakiraan pendapatan Cellectar Biosciences|BLRX: Rega forward marang dodolan|Multiplikator Forward P/S CANF|Multiplikator Forward P/S aprea.com (APRE)|Rasio rega marang prakiraan pendapatan Kazia Therapeutics Limited KZIA|SLXN (Silexion Therapeutics Corp.) - Rega mangsa ngarep marang pendapatan|NCNA: Multiplikator forward rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep chimerix.com|Cyclacel (CYCC) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan GTHX|Multiplikator forward rega marang pendapatan KRON|Multiplikator Forward P/S Kintara Pharma|Multiplikator forward rega marang pendapatan ONCT (Oncternal Therapeutics)|Rasio rega marang prakiraan pendapatan PRTG (portagebiotech.com)